MWG Management Ltd.

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), MWG Management Ltd. reported 3 stock positions worth $91.6 million. Its top holding was Beam Therapeutics (BEAM) at 58.0% of the portfolio, followed by Lyell Immunopharma (LYEL, 31.9%) and Prime Medicine (PRME, 10.1%). Compared with Q1 2024, it reduced 1. The biggest sale was Beam Therapeutics (BEAM, shares −3%).

Most Recent 13F
Q3 2025
Location
Washington, DC
CIK
0001845151
Portfolio Value
$91.6M (Q2 2024)
SEC Filing
0000950123-24-008094 ↗ filed Aug 13, 2024

Holdings Value

0$50.0M$100.0M$150.0M Q1 2024: $135.1M Q1 2024 Q2 2024: $91.6M $91.6M Q2 2024 Q3 2024: $90.3M Q3 2024 Q4 2024: $74.4M Q4 2024 Q1 2025: $58.7M Q1 2025 Q2 2025: $51.9M Q2 2025 Q3 2025: $81.3M Q3 2025

Holdings 3 stocks · $91.6M
BEAM Beam Therapeutics Inc. 58.01% 2,266,934 $53.1M Reduce -3.4%
LYEL Lyell Immunopharma Inc. 31.93% 20,162,332 $29.2M No change
PRME Prime Medicine Inc. 10.06% 1,792,210 $9.2M No change

Portfolio Sells Q1 2024 → Q2 2024
BEAM Beam Therapeutics Inc. Reduce -3.4% 58.01% +0.59

Portfolio Buys Q1 2024 → Q2 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2025 3$81.3MBEAM, LYEL, PRME
Q2 2025 3$51.9MBEAM, LYEL, PRME
Q1 2025 3$58.7MBEAM, LYEL, PRME
Q4 2024 3$74.4MBEAM, LYEL, PRME
Q3 2024 3$90.3MBEAM, LYEL, PRME
Q2 2024 3$91.6MBEAM, LYEL, PRME
Q1 2024 3$135.1MBEAM, LYEL, PRME